Wednesday, May 15, 2013 11:43:27 AM
Revenue for the three months ended March 31, 2013 was $1.3 million, compared to $1.5 million in the first quarter of 2012, and the operating loss for the quarter was $5.8 million, compared to $5.5 million for the comparable quarter last year.
During the first quarter, SIGA announced the delivery of approximately 190,000 courses of Arestvyr(TM) to the United States Government's Strategic National Stockpile under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA). This delivery represents the first of a series of planned deliveries of SIGA's proprietary smallpox antiviral drug.
Key Financial Results for First Quarter 2013
Revenues
For the quarters ended March 31, 2013 and 2012, revenue was $1.3 million and $1.5 million, respectively, a decrease of $137,000. Revenues decreased mainly due to a decrease in revenues from our federal contracts supporting the development of Arestvyr(TM).
Research and Development
Research and development expenses were $3.6 million for the three months ended March 31, 2013, a decrease of $819,000 from the $4.5 million incurred for the three months ended March 31, 2012. The decrease was mostly attributable to a decrease in direct vendor-related expenses supporting the development of Arestvyr, dengue antivirals and Lassa fever antivirals.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended March 31, 2013 and 2012 were $3.0 million and $2.2 million, respectively, reflecting an increase of $817,000. The increase in SG&A expenses primarily relates to a $310,000 increase in non-cash stock-based compensation, a $230,000 increase in other employee-related compensation and $215,000 of expenses related to the relocation of our corporate headquarters.
Patent Preparation Expenses
Patent preparation expenses for the quarter were $458,000, compared to $336,000 for the same period last year, mainly due to our ongoing efforts to protect our lead drug candidates in expanded geographic territories.
Financial Condition and Liquidity
Cash, cash equivalents and short-term investments on March 31, 2013 were $24.7 million, compared to $32.0 million on December 31, 2012.
Quarterly Report on Form 10-Q
SIGA is filing today with the Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013. SIGA urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K and its amended filing on Form 10-K/A for the year ended December 31, 2012. The amended filing on Form 10-K/A, which was also filed with the SEC today, provides further details concerning the Company and is consistent with our prior disclosures. The First Quarter Report on Form 10-Q, the Annual Report on Form 10-K and the amended filing on Form 10-K/A are also available on the Company's website, at www.siga.com.
About SIGA Technologies, Inc.
In the United States and around the globe, populations face a serious but unmet need for new drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. We are a pharmaceutical company specializing in developing pharmaceutical solutions for some of the most lethal disease causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, manufacture and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. For more information about SIGA, please visit SIGA's web site at www.siga.com.
The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504
Recent SIGA News
- SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- SIGA Names Larry Miller General Counsel • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- SIGA Declares Special Cash Dividend of $0.60 Per Share • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 08:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:04:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:28 PM
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:49:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:39 PM
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/26/2023 11:30:00 AM
- SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 10:05:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:05:20 PM
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 08:08:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 11:08:07 AM
- SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX® • GlobeNewswire Inc. • 07/27/2023 08:45:00 PM
- SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 07/27/2023 11:30:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM